Equities research analysts expect that Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) will report earnings per share of $2.91 for the current quarter, according to Zacks Investment Research. Eight analysts have made estimates for Jazz Pharmaceuticals’ earnings. The highest EPS estimate is $3.04 and the lowest is $2.83. Jazz Pharmaceuticals reported earnings of $2.95 per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 1.4%. The business is scheduled to report its next quarterly earnings report on Tuesday, February 26th.
According to Zacks, analysts expect that Jazz Pharmaceuticals will report full year earnings of $12.98 per share for the current year, with EPS estimates ranging from $12.89 to $13.10. For the next financial year, analysts forecast that the company will report earnings of $13.82 per share, with EPS estimates ranging from $13.05 to $14.78. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Jazz Pharmaceuticals.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.32 by $0.26. Jazz Pharmaceuticals had a net margin of 28.09% and a return on equity of 24.92%. The company had revenue of $469.37 million during the quarter, compared to analysts’ expectations of $482.64 million. During the same period last year, the company posted $3.22 earnings per share. Jazz Pharmaceuticals’s quarterly revenue was up 14.0% on a year-over-year basis.
JAZZ stock traded down $1.15 during trading on Friday, hitting $143.50. 1,114,128 shares of the company’s stock traded hands, compared to its average volume of 522,401. Jazz Pharmaceuticals has a 52 week low of $130.15 and a 52 week high of $184.00. The company has a quick ratio of 4.16, a current ratio of 4.29 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $8.73 billion, a P/E ratio of 15.01, a price-to-earnings-growth ratio of 0.87 and a beta of 0.94.
In other news, CEO Bruce C. Cozadd sold 1,300 shares of the firm’s stock in a transaction dated Friday, September 21st. The shares were sold at an average price of $164.36, for a total value of $213,668.00. Following the completion of the sale, the chief executive officer now owns 281,215 shares in the company, valued at approximately $46,220,497.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Matthew P. Young sold 700 shares of the firm’s stock in a transaction dated Friday, November 23rd. The stock was sold at an average price of $150.00, for a total transaction of $105,000.00. Following the completion of the sale, the chief financial officer now owns 32,068 shares of the company’s stock, valued at approximately $4,810,200. The disclosure for this sale can be found here. Insiders sold a total of 6,600 shares of company stock valued at $1,063,472 in the last 90 days. Company insiders own 3.90% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in JAZZ. Aperio Group LLC increased its holdings in shares of Jazz Pharmaceuticals by 19.3% during the 2nd quarter. Aperio Group LLC now owns 11,069 shares of the specialty pharmaceutical company’s stock valued at $1,907,000 after acquiring an additional 1,787 shares during the last quarter. Tdam USA Inc. increased its holdings in shares of Jazz Pharmaceuticals by 14.8% during the 2nd quarter. Tdam USA Inc. now owns 2,818 shares of the specialty pharmaceutical company’s stock valued at $486,000 after acquiring an additional 363 shares during the last quarter. TD Asset Management Inc. increased its holdings in shares of Jazz Pharmaceuticals by 9.1% during the 2nd quarter. TD Asset Management Inc. now owns 51,612 shares of the specialty pharmaceutical company’s stock valued at $8,892,000 after acquiring an additional 4,321 shares during the last quarter. Crossmark Global Holdings Inc. acquired a new position in shares of Jazz Pharmaceuticals during the 2nd quarter valued at about $429,000. Finally, Comerica Bank acquired a new position in shares of Jazz Pharmaceuticals during the 2nd quarter valued at about $436,000. Hedge funds and other institutional investors own 91.53% of the company’s stock.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Featured Article: Investing in Growth Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.